Keeping Pace: The Role of Immunotherapy After Disease Progression

Keeping Pace: The Role of Immunotherapy After Disease Progression

Keeping Pace: The Role of Immunotherapy After Disease Progression
RestartResume

PD-L1 expression can complicate treatment strategies in NSCLC. Find out what the latest clinical data is showing about newer checkpoint inhibitors.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression.

    This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mark A. Socinski, MD
    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL

    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novartis 
    Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Faculty:
    Edward B. Garon, MD
    Director of Thoracic Oncology
    David Geffen School of Medicine at UCLA
    Los Angeles, CA 

    Consulting Fees: Dracen Pharmaceutical, EMD Serono, GSK, Novartis
    Contracted Research: AstraZeneca, BMS, Eli Lilly, EMD Serono, Genentech, Iovance Biotherapeutics, Merck, Mirati Therapeutics Inc, Neon, Novartis 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • William A. Mencia, MD, has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • The Postgraduate Institute for Medicine planners and managers have nothing to disclose. 
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Determine appropriate combination or monotherapy strategies for use of immunotherapy in first-line or subsequent lines of therapy.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pulmonologists, pathologists, nurses, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and The Postgraduate Institute for Medicine. GLC is accredited by the ACCME to provide continuing medical education for physicians. 

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Learning Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Pharmacy Education

    This activity is approved for 0.25 contact hours (0.025 CEUs) for ACPE credit and 0.2 contact hours for ANCC credit. 

    (Universal Activity Number - JA4008162-9999-20-2189-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and The Postgraduate Institute for Medicine. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Myers Squibb, Lilly, and Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free